This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Dosing           DosingIBRANCE® Dosing
 
Monitoring Requirements
Safety            
SafetyIBRANCE® Safety ProfileNeutropeniaAdverse Event ManagementReal World EvidenceReal World EvidenceIBRANCE® Real World EvidenceP-VERIFYDuration of TreatmentP-REALITY X

Menu

Close

Clinical Trials
Clinical TrialsIBRANCE® Clinical TrialsIBRANCE® PALOMA-2 Trial
 
IBRANCE® PALOMA-3 TrialPatient ProfilesThe Ibrance® PatientPatient ProfilesAllison - Postmenopausal with comorbiditiesBecky - Postmenopausal with bone-only diseaseELEVATE MasterclassSupport and ResourcesSupport and ResourcesIBRANCE Service SupportMaterials
 
Videos

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics. IBRANCE® (palbociclib) Prescribing Information for the UK click here.  Adverse event reporting information can be found at the bottom of the page.

Ibrance® (palbociclib) Real-World Evidence


RWE and data from RCTs each have their own complementary strengths and weaknesses that, when combined, can help regulators, clinicians and patients to better understand and utilise therapies. 

Please note, observational retrospective analyses are not intended for direct comparison with clinical trials due to differences in study design and settings.

P-VERIFY

The Largest Real-World Comparative Overall Survival Analysis of First-line CDK4/6 Inhibitors + AI in HR+/HER2- mBC to Date

 Learn moreLoadingDuration of Treatment

Treatment duration and subsequent treatments of 1L CDK4/6 Inhibitor + AI for HR+/HER2- mBC
 

 Learn moreLoadingP-REALITY X

Palbociclib Real-World First-Line Comparative Effectiveness Study Extended
 

 Learn moreLoadingRandomised clinical trials (RCTs) and real world evidence (RWE) studies across the world have included patients with mBC treated with IBRANCE

Study numbers represent the number of patients treated with IBRANCE® + AI (n) and the total number of patients in each study (N), as of July 2025.​
* In PARSIFAL-LONG, 209 patients received IBRANCE® + letrozole.2

Strengths and Limitations of RCTs and RWD Studies Perspective on Clinical Trials and Real-World Data   

*Percentage estimated from 67,652 patients with cancer who were recruited into clinical trials in England in the financial year 2018-20194 and 305,683 people diagnosed in with in England in 20175

AI, aromatase inhibitor; mBC, metastatic breast cancer; RCT, randomised controlled trial; RWE, real-world evidence; RWD, real-world data

References

Clinicaltrials.gov NCT01740427. Available at: https://clinicaltrials.gov/study/NCT01740427#contacts-and-locations (accessed April 2026).Llombart-Cussac A, et al. ESMO Open. 2025;10(7):105309.Rugo HS, et al. ESMO Open. 2025;10(1):104103. Rugo HS, et al. NPJ Breast Cancer. 2022;8:114.Brufsky AM, et al. Cancer Med. 2025;14:e70719.Dent S, et al. Cardio-Oncology. 2025;11:7.Dent S, et al. Cardio-Oncology. 2025;11:64.Caillet P, et al. J Clin Oncol. 2021;39:Suppl 15;1012.Kennedy-Martin T, et al. Trials. 2015;16:495.Khozin S, et al. J Natl Cancer Inst. 2017;109; doi: 10.1093/jnci/djx187.Singal AG, et al. Clin Transl Gastroenterol. 2014;5:e45.The Institute of Cancer Research. Clinical trials in cancer. December 2021. Available at: https://www.icr.ac.uk/docs/default-source/migrated-documents/corporate-docs--accounts--and-annual-r… [Accessed April 2026].Office for National Statistics. Cancer registration statistics, England 2017. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2017 [Accessed April 2026].Booth CM, Tannock IF. Br J Cancer. 2014;110:551–555.AkobengAK. Arch Dis Child 2005;90:840–844.Sanson-Fisher RW, et al. Am J Prev Med 2007;33:155–161.SchmidtAF, et al. J Clin Epidemiol 2013;66:599–607.Valentgas P, et al. Making informed decisions:assessing the strengths and weaknesses of study designs and analytic methods for comparative effectiveness research. Available at:  www.npcnow.org/system/files/research/download/experimental_nonexperimental_study_final.pdf [Accessed April 2026].Brufsky A, et al. Presented at ESMO, Berlin, Germany, 17‒21 October 2025. Poster 523P

PP-IBR-GBR-6963. April 2026 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2026 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

UNP-GBR-13934. January 2026
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-13971. December 2025

YesNo
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​